EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm

Fadi G Haddad, Jennifer Croden, Koji Sasaki, Ghayas C Issa, Naveen Pemmaraju, Hagop Kantarjian, Elias Jabbour

Clinical Lymphoma Myeloma and Leukemia · 2026-01 · 26 (1) · 19-25

DOI: 10.1016/j.clml.2025.07.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-01. Verfasst von Fadi G Haddad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fhaddad@mdanderson.org. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pregnancy Complications, Neoplastic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Philadelphia chromosome-positive chronic myeloid leukemia (CML) during pregnancy is rare, with an annual incidence of 1 per 100,000 pregnancies. Managing CML in pregnancy is challenging due to concerns about the teratogenicity of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). While some pregnant patients with chronic-phase CML may be managed with close monitoring and no therapy, others, particularly those diagnosed in the first trimester, may require treatment to prevent disease progression and maternal complications. Imatinib has been associated with an increased risk of congenital malformations when used in the first trimester; however, growing evidence support its safety later in the second and third trimesters. Similar to imatinib, nilotinib has limited placental transfer with no congenital malformations reported to date in women who received it later in pregnancy. Dasatinib, however, is contraindicated due to its high association with congenital abnormalities and hydrops fetalis. Ponatinib exposure has been linked to a higher incidence of Hirschsprung's disease and should be avoided in pregnancy. Although no congenital malformations have been reported with bosutinib or asciminib, data remains limited, and their use is not recommended. Interferon-α is a safer alternative during pregnancy but is slower in achieving cytoreduction, and less effective compared to TKIs. Hydroxyurea, while not teratogenic, may increase the risk of miscarriage and low birth weight. If a male patient is receiving TKI therapy, the female partner can safely become pregnant without an increased risk for the fetus. Shared decision-making and thorough counseling on the risks and benefits of different treatment options are essential. This review examines the potential fetotoxicity of CML therapies, focusing on TKIs and alternative treatments for pregnant women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositivePregnancy Complications, NeoplasticHumansPregnancyFemaleAlgorithmsProtein Kinase InhibitorsDisease Management

Stichwörter der Autor:innen

BCR::ABL1CML-CPConceiveFetusPregnant

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fhaddad@mdanderson.org.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • NCI NIH HHS
  • NIH NCI

Zitieren

APA

Haddad, F. G., Croden, J., Sasaki, K., Issa, G. C., Pemmaraju, N., Kantarjian, H., & Jabbour, E. (2026). Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. Clinical Lymphoma Myeloma and Leukemia, 26(1), 19-25. https://doi.org/10.1016/j.clml.2025.07.017

Vancouver

Haddad FG, Croden J, Sasaki K, Issa GC, Pemmaraju N, Kantarjian H, et al. Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. Clinical Lymphoma Myeloma and Leukemia. 2026;26(1):19-25. doi:10.1016/j.clml.2025.07.017

BibTeX
@article{Haddad2026,
  author = {Haddad, Fadi G and Croden, Jennifer and Sasaki, Koji and Issa, Ghayas C and Pemmaraju, Naveen and Kantarjian, Hagop and Jabbour, Elias},
  title = {Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {19--25},
  doi = {10.1016/j.clml.2025.07.017}
}
Kostenlos starten →